Par to take over Edict Pharma
Edict Pharma is an India-based developer and manufacturer of solid oral dosage generic pharmaceuticals. With this acquisition, Par expects to strengthen its R&D business and enhance its manufacturing
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic therapy.
Nitrofurantoin oral suspension is an anti-bacterial medication indicated for the treatment of urinary tract infection. Amneal’s Nitrofurantoin oral suspension is generic version and therapeutically equivalent alternative to Furadantin
Elekta‘s integrated Oncology Information Systems features a complete, patient-centric chart optimized for medical oncology, radiation oncology and comprehensive practices. Elekta claims MOSAIQ’s single-database EHR can perform clinical decision
KODAK Security Solutions expertise in material science, digital imaging, document imaging, and graphic communications to create a portfolio of products and technologies that protect against counterfeiting. Kodak Business